mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 601–700 of 1,062
Jiménez-Sánchez, L., Campa, L., Auberson, Y. P., & Adell, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.123 · Cited by 85
“Previous work had already demonstrated that Ro 25- 6981 possessed antidepressant-like properties in the FST, the novelty-suppressed feeding test (NFST) and the deficit in sucrose consumption elicited by chronic unpredictable stress (Li et al., 2010, 2011).”
InfluentialmTORC1 senses stresses: Coupling stress to proteostasis
Su, K., & Dai, C. (2017) · BioEssays · doi:10.1002/bies.201600268 · Cited by 86
“Supporting a causative role of mTORC1 suppression in depressive disorders, ketamine, a Nmethyl-D-aspartic acid receptor (NMDAR) antagonist that is currently on clinical trials for treating major depressive disorder (MDD), activates mTORC1 in the PFC of rats, which underlies its rapid antidepressant effects [101].”
BackgroundPharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
Yamanaka, H., Yokoyama, C., Mizuma, H., Kurai, S., Finnema, S. J., Halldin, C., Doi, H., & Onoe, H. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.112 · Cited by 84
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Isoflurane produces antidepressant effects and induces TrkB signaling in rodents
Antila, H., Ryazantseva, M., Popova, D., Sipilä, P., Guirado, R., Kohtala, S., Yalcin, I., Lindholm, J., Vesa, L., Sato, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08166-9 · Cited by 84
An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress
Lu, J., Tjia, M., Mullen, B., Cao, B., Lukasiewicz, K., Shah-Morales, S., Weiser, S., Cameron, L. P., Olson, D. E., Chen, L., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01159-1 · Cited by 84
“Ketamine, an NMDA receptor antagonist, similarly enhances spine formation [73, 74], which is postulated to underlie its fast-acting antidepressant effect [61], although its primary target differs from that of psychedelics.”
BackgroundLi, Y., Pehrson, A. L., Waller, J. A., Dale, E., Sánchez, C., & Gulinello, M. E. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00279 · Cited by 84
Holz, A., Mülsch, F., Schwarz, M. K., Hollmann, M., Döbrössy, M. D., Coenen, V. A., Bartos, M., Normann, C., Biber, K., van Calker, D., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.011 · Cited by 79
Tang, X.-H., Zhang, G.-F., Xu, N., Duan, G.-F., Jia, M., Liu, R., Zhou, Z.-Q., & Yang, J.-J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01843-z · Cited by 79
Self-citationKouba, B. R., Camargo, A., Gil‐Mohapel, J., & Rodrigues, A. L. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137077 · Cited by 86
“Although this study did not explore the mechanisms underlying this, it is known that activated TrkB can phosphorylate and activate the mammalian target of rapamycin (mTOR), resulting in the translation of synaptic proteins, including postsynaptic density protein-95 kDa (PSD-95), glutamate α-amino-3-hydroxy-5-methyl-4-…”
Filipović, D., Zlatković, J., Gass, P., & Inta, D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.033 · Cited by 84
Choi, M., Lee, S. H., Wang, S. E., Ko, S. Y., Song, M., Choi, J.-S., Kim, Y.-S., Duman, R. S., & Son, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513913112 · Cited by 77
“In support of this possibility, ketamine is reported to increase the number of dendritic spines in neurons (4, 24), and many of the identified MEF2 targets are enriched in synapses (14).”
BackgroundResultSelf-citationCaraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
“Ketamine rapidly activates synaptic plasticity mediated by glutamatergic receptors, leading to increased number and function of new spine synapses (Li et al., 2010).”
BackgroundPhysical Exercise Prevented Stress‐Induced Anxiety via Improving Brain RNA Methylation
Yan, L., Wei, J., Yang, F., Wang, M., Wang, S., Cheng, T., Liu, X., Jia, Y., So, K., & Zhang, L. (2022) · Advanced Science · doi:10.1002/advs.202105731 · Cited by 83
Yang, A. J. T., Bagit, A., & MacPherson, R. E. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094628 · Cited by 83
Nikkheslat, N. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 71
Ketamine, magnesium and major depression – From pharmacology to pathophysiology and back
Murck, H. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.02.015 · Cited by 83
Xue, W., Zhou, X., Yi, N., Jiang, L., Tao, W., Wu, R., Wang, D., Jiang, J., Ge, X., Wang, Y., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/184367 · Cited by 83
“For example, mTOR signaling is also implicated in rapid and lasting antidepressant response [8].”
BackgroundMillan, M. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 79
“, 2011) – are implicated in the actions of ketamine (Maeng et al., 2008; Li et al., 2010; Aan Het Rot et al., 2012).”
Backgroundvan Schalkwyk, G. I., Wilkinson, S. T., Davidson, L., Silverman, W. K., & Sanacora, G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.023 · Cited by 76
Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23
Deyama, S., Shimoda, K., Suzuki, H., Ishikawa, Y., Ishimura, K., Fukuda, H., HitoraーImamura, N., Ide, S., Satoh, M., Kaneda, K., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4774-7 · Cited by 83
Antidepression action of BDNF requires and is mimicked by Gαi1/3 expression in the hippocampus
Marshall, J. J., Zhou, X., Chen, G., Yang, S., Li, Y., Wang, Y., Zhang, Z.-Q., Jiang, Q., Birnbaumer, L., & Cao, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722493115 · Cited by 85
“Depression is associated with a decrease in hippocampal spine density (50), and rapid BDNF-induced changes in dendrite complexity and spine density have been linked to the mechanism of fast-acting antidepressants (51, 52).”
BackgroundPsychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“This highlights the role of BDNF as a point of convergence for psychedelics and ketamine effects on dendrites (Ali et al., 2020; Savalia et al., 2021), BDNF signaling pathways (Li et al., 2010; Wang et al., 2022), and structural neural plasticity (Li et al., 2010; Phoumthipphavong et al., 2016).”
Aguilar-Valles, A., Haji, N., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Popic, J., Sharma, V., Cao, R., Rummel, C., Tanti, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04883-5 · Cited by 82
Ng, L. H. L., Huang, Y., Han, L., Chang, R. C.-C., Chan, Y. S., & Lai, C. S. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0321-5 · Cited by 82
Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
“One hypothesis for (R,S)‐ketamine's antidepressant mechanism of action is via inhibition of NMDA receptors (Autry et al., 2011; Li et al., 2010; Maeng et al., 2008; also see Zanos & Gould, 2018).”
BackgroundFogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82
“Ketamine produces a rapid (30 min) and transient (back to baseline by 2 h) activation of mTORC1 signaling, but a sustained increase in synaptic number and function (2 h to 7 days) that is associated with the rapid and sustained antidepressant actions of ketamine [10, 13].”
BackgroundMethodSelf-citationLeschik, J., Lutz, B., & Gentile, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147339 · Cited by 83
Astrocytes and major depression: The purinergic avenue
Zhao, Y. F., Verkhratsky, A., Tang, Y. C., & Illés, P. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109252 · Cited by 83
The Roles of Neurotrophic Factor and Wnt Signaling in Depression
Voleti, B., & Duman, R. S. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.296 · Cited by 77
Self-citationSałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.037 · Cited by 77
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., Deng, C., Hay, J., Ponton, R., Kirk, I. J., et al. (2020) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.07.002 · Cited by 71
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2013) · Journal of Molecular Psychiatry · doi:10.1186/2049-9256-1-15 · Cited by 81
“through the mechanistic target of rapamycin complex 1 (mTORC1) pathway [4,5], which is a ubiquitously expressed serine/threonine kinase pathway involved in regulation of cell growth and protein translation.”
BackgroundSelf-citationOral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Rawat, R., Tunc‐Ozcan, E., McGuire, T. L., Peng, C., & Kessler, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-30386-5 · Cited by 81
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
Duek, O. A., Korem, N., Li, Y., Kelmendi, B., Amen, S. L., Gordon, C., Milne, M., Krystal, J. H., Levy, I., & Harpaz‐Rotem, I. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01606-3 · Cited by 82
“Moreover, accumulating evidence suggests that on the molecular level, ketamine, in sub-anesthetic doses, promotes neurogenesis [28, 29], cell proliferation [30], and synaptogenesis [29, 31], all of which are important in reconsolidation processes [32, 33].”
BackgroundRamsey, A. J., Milenkovic, M., Oliveira, A. F., Escobedo-Lozoya, Y., Seshadri, S., Salahpour, A., Sawa, A., Yasuda, R., & Caron, M. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012621108 · Cited by 75
“Furthermore, acute NMDA receptor antagonism with ketamine has recently been shown to increase spine density, at least transiently, in the cortex (35).”
BackgroundLong-Term Continuous Corticosterone Treatment Decreases VEGF Receptor-2 Expression in Frontal Cortex
Howell, K. R., Kutiyanawalla, A., & Pillai, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020198 · Cited by 75
Giese, M., Beck, J., Brand, S., Muheim, F., Hemmeter, U., Hatzinger, M., Holsboer-Trachsler, E., & Eckert, A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.005 · Cited by 73
Zhong, X., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., Zhang, M., & Huang, X. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.011 · Cited by 81
da Rosa, P. B., Neis, V. B., Ribeiro, C. M., Moretti, M., & Rodrigues, A. L. S. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.05.010 · Cited by 81
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74
Adaikkan, C., Taha, E., Barrera, I., David, O., & Rosenblum, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.028 · Cited by 76
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
López-Gil, X., Jiménez-Sánchez, L., Campa, L., Castro, E., Frago, C., & Adell, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00288 · Cited by 80
iPlasticity: Induced juvenile‐like plasticity in the adult brain as a mechanism of antidepressants
Umemori, J., Winkel, F., Didio, G., Llach Pou, M., & Castrén, E. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12683 · Cited by 80
Xie, Z.-M., Wang, X.-M., Xu, N., Wang, J., Pan, W., Tang, X.-H., Zhou, Z.-Q., Hashimoto, K., & Yang, J.-J. (2017) · Scientific Reports · doi:10.1038/s41598-017-03590-3 · Cited by 71
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 82
Mogha, A., Guariglia, S. R., Debata, P. R., Wen, G. Y., & Banerjee, P. (2012) · Translational Psychiatry · doi:10.1038/tp.2011.58 · Cited by 68
“Our experiments have used ketamine for anesthesia and a recent study has demonstrated ketamine regulates hippocampal synapse formation.(55) As both control and 5-HT1A agonist-treated mice used in our experiments were anesthetized using the same concentration of ketamine, it is unlikely that a different anesthetic woul…”
Retrograde Changes in Presynaptic Function Driven by Dendritic mTORC1
Henry, F. E., McCartney, A. J., Neely, R., Perez, A. S., Carruthers, C. J. L., Stuenkel, E. L., Inoki, K., & Sutton, M. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2149-12.2012 · Cited by 71
“, 2003), and that loss of NMDAR activity in cortical neurons can also activate mTORC1 signaling (Li et al., 2010; Wang et al., 2011).”
BackgroundRepeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice
Thelen, C., Sens, J. P., Mauch, J., Pandit, R., & Pitychoutis, P. M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.041 · Cited by 80
Braidy, N., Essa, M. M., Poljak, A., Subash, S., Al‐Adawi, S., Manivasagm, T., Thenmozhi, A. J., Ooi, L., Sachdev, P. S., & Guillemin, G. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10905 · Cited by 80
“Another protein associated with synaptic plasticity is mTOR [81, 82].”
RetractedHippocampal HDAC4 Contributes to Postnatal Fluoxetine-Evoked Depression-Like Behavior
Sarkar, A., Chachra, P., Kennedy, P., Pena, C. J., Desouza, L. A., Nestler, E. J., & Vaidya, V. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.73 · Cited by 79
“Clinical evidence indicates decreased cortical mTOR levels in depressed patients (Jernigan et al, 2011), whereas activation of mTOR signaling mediates the behavioral effects of rapid-action antidepressants (Li et al, 2010).”
BackgroundRapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
“CSNK1e phosphorylates BMAL1 and partially activates the transcription factor of BMAL1 (CSNK1e also phosphorylates PER1, PER2) (Eide et al. 2005; Takahashi, 2004).”
BackgroundInfluentialYamada, J., & Jinno, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107710 · Cited by 76
Gao, W., Yang, S.-S., Mack, N. R., & Chamberlin, L. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01196-w · Cited by 80
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“Given the doseresponse relationship between the glutamate surge, synaptogenesis, and antidepressant response following ketamine administration [28, 30, 54], it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
BackgroundInfluentialSelf-citationEffects of Inhibitor of κB Kinase Activity in the Nucleus Accumbens on Emotional Behavior
Christoffel, D. J., Golden, S. A., Heshmati, M., Graham, A., Birnbaum, S., Neve, R. L., Hodes, G. E., & Russo, S. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.121 · Cited by 78
Shen, J., Song, C., Lu, X., Wen, Y., Song, S., Yu, J., & Sun, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1038379 · Cited by 78
“antidepressant effects (10); (2) NMDA receptors are blocked and AMPA receptors are activated, and then neurotrophic effects are promoted, such as the release of brain-derived neurotrophic factor, eukaryotic elongation Factor 2, and other activated downstream nutrient signal cascades, resulting in dendritic growth and…”
BackgroundAdult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?
Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 78
Gilbert, J. R., & Zarate, C. A. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172856 · Cited by 73
“, 1997), thereby activating neuroplasticity-related signaling pathways including mammalian target of rapamycin complex 1 (Li et al., 2010; Li et al., 2011) and brain-derived neurotrophic factor (Liu et al.”
BackgroundKang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
“However, another study showed decreased levels of GLT-1 with ketamine exposure in the mPFC (64).”
BackgroundInfluentialGougol, A., Zareh-Mohammadi, N., Raheb, S., Farokhnia, M., Salimi, S., Iranpour, N., Yekehtaz, H., & Akhondzadeh, S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578160 · Cited by 77
“ketamine) is a promising strategy to achieve rapid antidepressant effects (Li et al., 2010).”
BackgroundKhlestova, E., Johnson, J. W., Krystal, J. H., & Lisman, J. E. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1203-16.2016 · Cited by 78
“Some antidepressant effects have been produced by relatively selective antagonists of GluN2B-containing NMDARs in animals (Li et al., 2010) and humans (Preskorn et al., 2008), suggesting that such NMDARs can affect depression.”
BackgroundBeurel, E., Grieco, S. F., Amadei, C., Downey, K., & Jope, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12436 · Cited by 76
Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior
Dwyer, J. M., Maldonado-Avilés, J. G., Lepack, A. E., DiLeone, R. J., & Duman, R. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505289112 · Cited by 76
“Psychopharmacology (Berl) 97(2):277–279.”
BackgroundInfluentialSelf-citationKetamine, Sleep, and Depression: Current Status and New Questions
Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0394-z · Cited by 76
Yoshino, Y., Roy, B., & Dwivedi, Y. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00861-y · Cited by 70
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 77
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 77
“In addition, these effects resulted in enhanced serotonergic neurotransmission observed at 24 h post ketamine injection, which represented a mechanism for the rapid antidepressant actions of ketamine (Li et al, 2010).”
Luoni, A., Macchi, F., Papp, M., Molteni, R., & Riva, M. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu061 · Cited by 70
“, 2011), and the modulation of mTOR pathway appears to be crucial for the rapid antidepressant activity of ketamine (Li et al., 2010).”
BackgroundInfluentialLu, Y., Wang, C., Xue, Z., Li, C., Zhang, J., Zhao, X., Liu, A., Wang, Q., & Zhou, W. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu110 · Cited by 75
“In addition, BDNF-induced TrkB activation stimulates the PI3K/ AKT signaling pathways, which play a principal role in promoting neuronal survival and synaptic plasticity and antidepressant-like actions (Numakawa et al., 2010, 2013), suggesting that VGF may feedback regulate the PI3K/AKT/mTOR signaling in hippocampus o…”
BackgroundInfluentialAlteration by p11 of mGluR5 localization regulates depression-like behaviors
Lee, K.-W., Westin, L., Kim, J., Chang, J. C., Oh, Y.-S., Amreen, B., Gresack, J. E., Flajolet, M., Kim, D. J., Aperia, A. C., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.132 · Cited by 76
Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
“At postsynaptic sites, ketamine transiently enhances glutamate release that activates AMPA receptors, thus increasing TrkB receptor stimulation, which in turn facilitates mammalian target of rapamycin complex (mTORC) signaling and enables translation and release of brain-derived neurotrophic factor (BDNF) [49].”
BackgroundEl Iskandrani, K. S., Oosterhof, C. A., El Mansari, M., & Blier, P. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573809 · Cited by 75
“In the case where 10 mg/kg (Li et al., 2010) did not induce any effect, 25 mg/kg dose of ketamine was used as in Gigliucci et al. (2013); at this dose, ketamine is still subanesthetic and produces a significant effect in the FST model (Li et al., 2010; Gigliucci et al., 2013).”
BackgroundMethodInfluentialJett, J. D., Boley, A. M., Girotti, M., Shah, A., Lodge, D. J., & Morilak, D. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3957-3 · Cited by 75
“It has been proposed that the therapeutic effects of ketamine result in part from enhanced glutamate neurotransmission and activation of the principal neurons in the mPFC and hippocampus (Moghaddam et al. 1997; Li et al. 2010).”
InfluentialTransient and sustained effects of dopamine and serotonin signaling in motivation‐related behavior
Yagishita, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12942 · Cited by 75
Orphan G Protein Coupled Receptors in Affective Disorders
Watkins, L. R., & Orlandi, C. (2020) · Genes · doi:10.3390/genes11060694 · Cited by 75
“The latest investigations into the rapid-acting and sustained effects of ketamine have helped discover new pathways that can lead to the identification of novel pharmacological targets [22,239].”
BackgroundA unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
Liu, S., Zhao, R., Li, X., Guo, H.-J., Tian, Z., Zhang, N., Gao, G., & Zhao, M. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8280-8 · Cited by 75
Self-citationDossat, A. M., Wright, K. N., Strong, C. E., & Kabbaj, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.022 · Cited by 72
“Previous reports posited that ketamine's up-regulation of AMPA receptor expression may underlie enhanced glutamatergic sensitivity and synaptic plasticity (Kavalali and Monteggia, 2012; Li et al., 2010).”
BackgroundResultInfluentialWhat Acute Stress Protocols Can Tell Us About PTSD and Stress-Related Neuropsychiatric Disorders
Musazzi, L., Tornese, P., Sala, N., & Popoli, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00758 · Cited by 76
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
Huang, Y.-J., Lane, H.-Y., & Lin, C.-H. (2017) · Neural Plasticity · doi:10.1155/2017/4605971 · Cited by 74
“A single dosage of ketamine can increase levels of postsynaptic density proteins, including activity-regulated cytoskeletal protein (Arc), glutamate-AMPA receptor-1 (GluR1), postsynaptic density protein-95 (PSD95), and synapsin I [37].”
BackgroundInfluentialA New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“It modulates cortical function by increasing dendritic spine and synapse density in the PFC (Browne & Lucki, 2013; Li et al., 2010; Moda- Sava et al., 2019), and it has shown promise for treating addiction (Krupitsky et al., 2002) and PTSD (Feder et al., 2014) in addition to depression (Berman et…”
BackgroundPI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
Chen, Y., Guan, W., Wang, M., & Lin, X. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae010 · Cited by 76
“Similarly, other antidepressant treatments promote antidepressant behavioral responses via the activation of the PI3K/Akt/ mTOR signaling pathway (Figure 7) (Li et al., 2010).”
BackgroundLv, Q., Yang, L., Li, G., Wang, Z., Shen, Z., Yu, W., Jiang, Q., Hou, B., Pu, J., Hu, H., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.028 · Cited by 75
Koike, H., Iijima, M., & Chaki, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.017 · Cited by 75
Kislin, M., Mugantseva, E., Molotkov, D., Kulesskaya, N., Khirug, S., Kirilkin, I., Pryazhnikov, E., Kolikova, J., Toptunov, D., Yuryev, M. V., et al. (2014) · Journal of Visualized Experiments · doi:10.3791/51869 · Cited by 74
Soumier, A., Carter, R. M., Schoenfeld, T. J., & Cameron, H. A. (2016) · eneuro · doi:10.1523/eneuro.0116-15.2016 · Cited by 67
“This model is supported by findings that AMPA receptor activation is required for the antidepressant effects of ketamine (Maeng et al., 2008; Li et al., 2010; Autry et al., 2011; Koike et al., 2011).”
BackgroundMethodInfluentialMarek, G. J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_480 · Cited by 75
The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
Fabbri, C., Corponi, F., Souery, D., Kasper, S., Montgomery, S., Zohar, J., Rujescu, D., Mendlewicz, J., & Serretti, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy024 · Cited by 59
“Ketamine rapidly activates the mammalian target of rapamycin pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses (Li et al., 2010).”
BackgroundTreccani, G., Ardalan, M., Chen, F., Musazzi, L., Popoli, M., Wegener, G., Nyengaard, J. R., & Müller, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1613-3 · Cited by 73
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview
Bortolozzi, A. A., Fico, G., Berk, M., Solmi, M., Fornaro, M., Quevedo, J., Zarate, C. A., Kessing, L. V., Vieta, E., & Carvalho, A. F. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000007 · Cited by 74
Gupta, S. C., Yadav, R., Pavuluri, R., Morley, B. J., Stairs, D. J., & Dravid, S. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.013 · Cited by 64
Yu, J.-J., Zhang, Y., Wang, Y., Wen, Z.-Y., Liu, X., Qin, J., & Yang, J.-L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2823-9 · Cited by 73
“Additionally, it has been indicated that NMDA receptor antagonist ketamine, a fast-acting antidepressant, increased synapse-associated protein synthesis and spine formation via activation of mTOR pathway in the mPFC in rats (Li et al. 2010), suggesting that mTOR signaling in the mPFC is linked to the antidepressant tr…”
Influential
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.